Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Tom Van Den Bosch"'
Autor:
Kristiaan J. Lenos, Sander Bach, Leandro Ferreira Moreno, Sanne ten Hoorn, Nina R. Sluiter, Sanne Bootsma, Felipe A. Vieira Braga, Lisanne E. Nijman, Tom van den Bosch, Daniel M. Miedema, Erik van Dijk, Bauke Ylstra, Ruth Kulicke, Fred P. Davis, Nicolas Stransky, Gromoslaw A. Smolen, Robert R. J. Coebergh van den Braak, Jan N. M. IJzermans, John W. M. Martens, Sally Hallam, Andrew D. Beggs, Geert J. P. L. Kops, Nico Lansu, Vivian P. Bastiaenen, Charlotte E. L. Klaver, Maria C. Lecca, Khalid El Makrini, Clara C. Elbers, Mark P. G. Dings, Carel J. M. van Noesel, Onno Kranenburg, Jan Paul Medema, Jan Koster, Lianne Koens, Cornelis J. A. Punt, Pieter J. Tanis, Ignace H. de Hingh, Maarten F. Bijlsma, Jurriaan B. Tuynman, Louis Vermeulen
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)
Colorectal cancer can lead to the development of peritoneal metastases, which are associated with worse disease outcome. Here, the authors characterize peritoneal metastases from 52 patients using RNA-seq and mutational sequencing and show a distinct
Externí odkaz:
https://doaj.org/article/369abe186b03465f8bac79e90a4d4606
Autor:
Erik van Dijk, Tom van den Bosch, Kristiaan J. Lenos, Khalid El Makrini, Lisanne E. Nijman, Hendrik F. B. van Essen, Nico Lansu, Michiel Boekhout, Joris H. Hageman, Rebecca C. Fitzgerald, Cornelis J. A. Punt, Jurriaan B. Tuynman, Hugo J. G. Snippert, Geert J. P. L. Kops, Jan Paul Medema, Bauke Ylstra, Louis Vermeulen, Daniël M. Miedema
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Intratumour heterogeneity (ITH) is associated with worse prognosis in cancer, and efficient frameworks to measure it are needed. Here the authors develop a method to estimate copy number heterogeneity, and propose that it is driven by chromosomal ins
Externí odkaz:
https://doaj.org/article/264d1331d97845559b189b69b84d9dcb
Autor:
Sophie C. Lodestijn, Daniël M. Miedema, Kristiaan J. Lenos, Lisanne E. Nijman, Saskia C. Belt, Khalid El Makrini, Maria C. Lecca, Cynthia Waasdorp, Tom van den Bosch, Maarten F. Bijlsma, Louis Vermeulen
Publikováno v:
Cell Reports, Vol 37, Iss 3, Pp 109852- (2021)
Summary: Effective treatments for pancreatic ductal adenocarcinoma (PDAC) are lacking, and targeted agents have demonstrated limited efficacy. It has been speculated that a rare population of cancer stem cells (CSCs) drives growth, therapy resistance
Externí odkaz:
https://doaj.org/article/80eedbc9d2e0414487e39ec48b1faf57
Publikováno v:
Molecular & Cellular Oncology, Vol 8, Iss 4 (2021)
We recently introduced a method to derive intra-tumor heterogeneity (ITH) from a single copy number measurement. This method stratifies patients for survival and could potentially help to identify low and high-risk patients with clinical relevance.
Externí odkaz:
https://doaj.org/article/6565d7e6ce88476081f21f138217e72c
Publikováno v:
British journal of cancer, 127(7), 1332-1339. Nature Publishing Group
Background: Endocrine therapy forms the backbone of adjuvant treatment for oestrogen-receptor-positive (ER+) breast cancer. However, it remains unclear whether adjuvant treatment improves survival rates in low-risk patients. Low intra-tumour heteroge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d666583b6baf6ee099088af33ead11a
https://pure.amc.nl/en/publications/copy-number-heterogeneity-identifies-er-breast-cancer-patients-that-do-not-benefit-from-adjuvant-endocrine-therapy(8608236a-4bb3-4f3f-bc50-30d2e7a79164).html
https://pure.amc.nl/en/publications/copy-number-heterogeneity-identifies-er-breast-cancer-patients-that-do-not-benefit-from-adjuvant-endocrine-therapy(8608236a-4bb3-4f3f-bc50-30d2e7a79164).html
Publikováno v:
van den Bosch, T, Derks, S & Miedema, D M 2022, ' Chromosomal Instability, Selection and Competition : Factors That Shape the Level of Karyotype Intra-Tumor Heterogeneity ', Cancers, vol. 14, no. 20, 4986 . https://doi.org/10.3390/cancers14204986
Intra-tumor heterogeneity (ITH) is a pan-cancer predictor of survival, with high ITH being correlated to a dismal prognosis. The level of ITH is, hence, a clinically relevant characteristic of a malignancy. ITH of karyotypes is driven by chromosomal
Publikováno v:
Journal of pathology, 257(5), 575-578. John Wiley and Sons Ltd
Overall, the prognosis of patients suffering from stage II colon cancer is relatively favorable. However, a proportion of patients develop a recurrence following surgery. Clinical and histopathological properties that identify high-risk patients are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::412e5bbd108ba5fdb85620d9a07d540c
https://pure.amc.nl/en/publications/copynumber-intratumor-heterogeneity-as-highrisk-feature-of-stage-ii-colon-cancer(dc553981-2c06-4238-b7c3-41b68f15b6dd).html
https://pure.amc.nl/en/publications/copynumber-intratumor-heterogeneity-as-highrisk-feature-of-stage-ii-colon-cancer(dc553981-2c06-4238-b7c3-41b68f15b6dd).html
Publikováno v:
Computational and Systems Oncology. 2
Autor:
Sanne ten Hoorn, Linda Mol, Dirkje W. Sommeijer, Lisanne Nijman, Tom van den Bosch, Tim R. de Back, Bauke Ylstra, Erik van Dijk, Carel J.M. van Noesel, Roy J. Reinten, Iris D. Nagtegaal, Miriam Koopman, Cornelis J.A. Punt, Louis Vermeulen
Publikováno v:
ten Hoorn, S, Mol, L, Sommeijer, D W, Nijman, L, van den Bosch, T, de Back, T R, Ylstra, B, van Dijk, E, van Noesel, C J M, Reinten, R J, Nagtegaal, I D, Koopman, M, Punt, C J A & Vermeulen, L 2022, ' Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial : Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer ', Clinical Colorectal Cancer . https://doi.org/10.1016/j.clcc.2022.11.006
Clinical colorectal cancer. Elsevier
Clinical Colorectal Cancer, 22, 1, pp. 67-75
Clinical Colorectal Cancer, 22, 67-75
Clinical Colorectal Cancer. Elsevier
Clinical colorectal cancer. Elsevier
Clinical Colorectal Cancer, 22, 1, pp. 67-75
Clinical Colorectal Cancer, 22, 67-75
Clinical Colorectal Cancer. Elsevier
Contains fulltext : 290951.pdf (Publisher’s version ) (Open Access) BACKGROUND: Here we present updated survival of the CAIRO2 trial and assessed whether the addition of anti-EGFR to anti-VEGF therapy could still be an effective treatment option fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7572ff40393021d942c81fa5a98366b4
https://research.vumc.nl/en/publications/78222ce6-256a-40ff-a6b0-90cb02d060ad
https://research.vumc.nl/en/publications/78222ce6-256a-40ff-a6b0-90cb02d060ad
Publikováno v:
Molecular & Cellular Oncology
article-version (VoR) Version of Record
Molecular & cellular oncology. Taylor and Francis Ltd.
article-version (VoR) Version of Record
Molecular & cellular oncology. Taylor and Francis Ltd.
We recently introduced a method to derive intra-tumor heterogeneity (ITH) from a single copy number measurement. This method stratifies patients for survival and could potentially help to identify low and high-risk patients with clinical relevance.